Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
martes, octubre 20
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Gossamer Bio Inc
GOSS
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$8.43
-0.34
-3.88%
Últ. Act.: Oct 20, 4:56 AM
$8.32
-0.45
-5.13%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Privacy Manager
Gossamer Bio Financials
Gossamer Bio (GOSS) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Gossamer Bio Q2 EPS $(0.08) Beats $(0.12) Estimate, Sales $9.238M Beat $5.193M Estimate
Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.12) by 33.33 percent. This is a 52.94 percent increase over losses of $(0.17) per share from the
Benzinga Newsdesk
PRO
Gossamer Bio Q1 EPS $(0.20) Misses $(0.13) Estimate, Sales $16.955M Beat $4.475M Estimate
Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.13) by 53.85 percent. This is a 25 percent decrease over losses of $(0.16) per share from the
Benzinga Newsdesk
PRO
Gossamer Bio Q4 EPS $(0.21) Misses $(0.18) Estimate, Sales $13.799M Beat $7.522M Estimate
Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.18) by 14.13 percent. This is a 40 percent decrease over losses of $(0.15) per share from the
Benzinga Newsdesk
PRO
Gossamer Bio Q3 EPS $(0.21) Misses $(0.18) Estimate, Sales $13.294M
Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.18) by 16.02 percent. This is a 50 percent decrease over losses of $(0.14) per share from the
Benzinga Newsdesk
PRO
Gossamer Bio Q2 EPS $(0.17) Beats $(0.18) Estimate, Sales $11.49M Beat $4.34M Estimate
Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.18) by 5.03 percent. This is a 177.27 percent decrease over earnings of $0.22 per share from the
Benzinga Newsdesk
PRO
Gossamer Bio Q1 EPS $(0.16) Beats $(0.18) Estimate, Sales $9.89M Beat $4.07M Estimate
Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.18) by 11.11 percent. This is a 15.79 percent increase over losses of $(0.19) per share from the
Benzinga Newsdesk
